project . 2022 - 2027 . Not started

PECAN

Exploring the Prokaryotic-Eukaryotic Conservation of Antiviral immunity: from bacterial immune systems to novel antiviral drugs
Open Access mandate for Publications and Research data
European Commission
Funder: European CommissionProject code: 101040529 Call for proposal: ERC-2021-STG
Funded under: HE | ERC | HORIZON-ERC\HORIZON-AG Overall Budget: 1,496,500 EURFunder Contribution: 1,496,500 EUR
Status: Not started
01 Oct 2022 (Started) 30 Sep 2027 (Ending)
Description
Bacteria have evolved multiple lines of defense against their viruses, bacteriophages. Such weapons include restriction modification and CRISPR systems that have greatly impacted biomedical research. Studies aimed at uncovering novel defense mechanisms describe an unsuspected diversity of anti-phage systems, spanning thousands of protein families. Several of these anti-phage systems, such as prokaryotic viperins, appear to be ancestors of major eukaryotic antiviral pathways. This striking conservation between eukaryotic and prokaryotic immunity leads me to two hypotheses on which the present proposal is based. First, I postulate that the organisation of antiviral immunity in eukaryotes as an immune system, i.e. an integrated network of various antiviral mechanisms, might be conserved in prokaryotes. This implies that each anti-phage system does not act in isolation, but is rather part of a whole, the bacterial immune system. To explore this hypothesis, I will characterise the distribution of known anti-phage systems encoded in prokaryotic genomes. I will subsequently explore the potential synergies and co-regulation existing between these systems. I thereby aim to build an integrated map of bacteria antiviral immunity. Second, I hypothesise that prokaryotes produce additional small anti-phage compounds, such as the viperin products, with a potential activity against eukaryotic viruses. To explore this idea, I will study the molecular mechanisms of the viperin family. I will then use genomics to predict novel chemical based anti-phage systems and follow up with their experimental characterizations. These projects could lead to the identification of novel antiviral molecules that could be further harnessed in the clinic. Overall, I expect this proposal to generate new knowledge that will have the potential to radically change our view on the immune systems of prokaryotes and provide new therapeutic leads.
Partners
Data Management Plans